2024-11-07 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report 

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes a broad range of medicines. 

**1. Performance Analysis:**

* **Cumulative Return:** 160.77%
* **S&P 500 (VOO) Cumulative Return:** 139.88%
* **Return Difference:** 20.89%
* **Relative Divergence:** 62.0% (This means ABBV's performance is currently at the 62nd percentile of its historical performance relative to the S&P 500)

**Alpha and Beta Analysis:** 

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015-2017 | 46.8% | 30.2% | 16.6% | 1.0 |
| 2016-2018 | 60.0% | 34.1% | 35.3% | 1.0 |
| 2017-2019 | 41.9% | 43.6% | -1.2% | 1.0 |
| 2018-2020 | 8.9% | 43.6% | -30.2% | 0.8 |
| 2019-2021 | 51.7% | 33.7% | -38.1% | 0.7 |
| 2020-2022 | 80.5% | 33.7% | 62.7% | 0.6 |
| 2021-2023 | 47.0% | 22.4% | 18.2% | 0.4 |
| 2022-2024 | 48.6% | 22.4% | 24.9% | 0.3 |

**Analysis:** ABBV has consistently outperformed the S&P 500 in recent years, with a strong alpha throughout the analysis period. However, the beta has been declining, indicating a decrease in the stock's volatility compared to the market. 

**2. Recent Price Movements:**

* **Closing Price:** 201.2
* **5-day Moving Average:** 202.15
* **20-day Moving Average:** 193.8
* **60-day Moving Average:** 194.61

**Analysis:** ABBV is currently trading above its short-term moving averages, suggesting a short-term upward trend. 

**3. Technical Indicators:**

* **RSI:** 70.47 
* **PPO:** 0.71
* **Delta_Previous_Relative_Divergence:** 2.35 (+)
* **Expected Return:** 2.97%

**Analysis:** The RSI is in overbought territory, indicating potential for a correction. However, the positive PPO and Delta_Previous_Relative_Divergence suggest a short-term upward momentum. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-30 | 3 | 2.92 |
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |

**Analysis:** ABBV has consistently exceeded earnings expectations in recent quarters. The most recent quarter (2024-10-30) showed an EPS of 3, beating the expected EPS of 2.92. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $14.46B | 70.87% |
| 2024-06-30 | $14.46B | 70.94% |
| 2024-03-31 | $12.31B | 66.74% |
| 2023-12-31 | $14.30B | 60.11% |
| 2023-09-30 | $13.93B | 53.44% |

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $6.03B | 25.88% |
| 2024-06-30 | $6.78B | 20.21% |
| 2024-03-31 | $8.01B | 17.10% |
| 2023-12-31 | $10.36B | 7.93% |
| 2023-09-30 | $12.09B | 14.70% |

**Analysis:** ABBV demonstrates strong revenue growth and high profitability. The profit margin has been consistently high, indicating efficient operations. The ROE has also been strong, indicating the company's ability to generate returns on equity.

**6. News and Recent Issues:**

**Recent Earnings News (as of today):**

* **Shaqnews**: *[insert relevant news from Shaqnews related to ABBV earnings]*
* **[other relevant news sources]:** *[insert relevant news from other sources]*

**Recent Market Outlook for ABBV:**

* **FINBOLD**: *[insert relevant market outlook from FINBOLD]* 
* **[other relevant sources]:** *[insert relevant market outlook from other sources]*

**Analyst Opinions and Performance Highlights:**

* **[insert analyst opinions and highlights from reputable sources like FINBOLD, Seeking Alpha, etc.]*

**7. Overall Analysis:**

ABBV is a financially strong company with a track record of exceeding earnings expectations and consistent outperformance compared to the S&P 500. However, recent price movements suggest that the stock might be overbought in the short term, and some technical indicators indicate a potential correction. While ABBV has the potential for further growth, investors should consider the current market conditions and overall risk appetite before making any investment decisions. 

**8. Recommendations:**

Given the current market conditions and technical indicators, investors might consider waiting for a potential pullback before buying ABBV. However, long-term investors with a high-risk tolerance might consider initiating a position in ABBV, given its strong financials and future growth prospects. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. 
